Phaseline

Companies › nChroma Bio

nChroma Bio: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Infectious disease; next expected readout Dec 2032.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
CRMA-1001
Epigenetic gene silencing therapy
–Phase 1Chronic Hepaititis BDec 2032

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07200193CRMA-1001Phase 1Chronic Hepaititis BInfectious diseaseDec 2032

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.